. Author manuscript; available in PMC: 2011 Feb 1.

Published in final edited form as: J Acquir Immune Defic Syndr. 2010 Feb 1;53(2):176–185. doi: 10.1097/QAI.0b013e3181c5c81f

Table 4.

Prevalence of congenital anomalies per 100 live births by trimester of first ARV exposure

Timing of first ARV exposure	Congenital anomalies (outcomes ≥20 weeks)	Women first exposed to ARVs during this period	Women exposed to ARVs during this period who had live births	Congenital anomalies per 100 live births (95% CI)*
1^st trimester	15	249	242	6.20 (3.06–9.34)
2^nd trimester	35	530	518	6.76 (4.52–9.00)
3^rd trimester	9	209	208	4.33 (1.5–7.15)
No exposure	1	7	6	16.67 (0–49.33)
TOTAL	60	995	974	6.16 (4.60–7.72)